PO:07:103 | Tocilizumab use in patients with rheumatoid arthritis and malignancy: a monocentric experience
Background. In 2024, the EULAR published a set of points to consider for initiating targeted therapy in rheumatoid arthritis (RA) patients with a history of malignancy, indicating TNF inhibitors are preferred in solid tumors, while rituximab is recommended for hematological malignancies. Although t...
Furkejuvvon:
| Váldodahkki: | |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
PAGEPress Publications
2025-11-01
|
| Ráidu: | Reumatismo |
| Fáttát: | |
| Liŋkkat: | https://www.reumatismo.org/reuma/article/view/2021 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|